Introduction
While M&A transactions generate the biggest headlines, licensing deals are the highest-volume transaction type in pharmaceutical business development. J.P. Morgan's Q4 2025 biopharma licensing report counted 516 licensing deals with $250.2 billion in announced value in 2025, against 129 biopharma acquisitions worth $138 billion: roughly four licenses for every acquisition. These agreements let pharma companies access external pipeline assets without buying the whole company, and they let biotechs fund development and reach commercial infrastructure without selling the business.
Healthcare bankers advise on licensing deal structures, negotiate financial terms, and help clients decide whether licensing or full acquisition is the better route to an external asset. This article takes the pharma buyer's seat; the licensor's decisions (when to partner, and how terms shift by clinical stage) sit in biotech partnering and licensing.
Anatomy of a Licensing Deal
A standard pharma licensing deal has three financial components that collectively determine the total deal economics, plus add-on terms that can shift them.
Upfront Payment
The initial cash payment at deal signing. Upfront payments serve as the "price of admission" for the licensee and provide immediate funding to the licensor for ongoing development. In most deals the upfront is the only non-contingent money, which is why experienced licensors fight harder over it than over the headline total.
- Range: $10 million (early preclinical) to $1 billion+ (Phase III, commercial stage, or a hotly contested asset)
- Determinants: Development stage, therapeutic area, competitive landscape for the asset, and the licensor's alternatives (other potential partners, IPO/financing options)
Milestone Payments ("Biobucks")
Contingent payments triggered by specific development, regulatory, or commercial achievements. Milestones make up most of the "biobucks" figure that press releases headline.
- Biobucks
The total potential value of a pharma licensing deal, including the upfront payment and all development, regulatory, and commercial milestones. Biobucks are the headline number in deal announcements but overstate expected value because most milestones depend on uncertain outcomes: a deal "worth up to $3 billion" might carry a probability-weighted value of $500 million-$1 billion, depending on development stage.
The gap between headline and guaranteed money is wide. In J.P. Morgan's 2025 data, upfront payments held at about 7% of total announced deal value, and headline growth came mainly from expanded milestone packages. Milestones are typically structured in tiers:
| Milestone Type | Examples | Typical Range |
|---|---|---|
| Development | Phase I initiation, Phase II data, Phase III initiation | $10-100M each |
| Regulatory | NDA/BLA filing, FDA approval, EMA approval, Japan approval | $50-200M each |
| Commercial | First $500M in annual sales, first $1B in annual sales | $50-300M each |
Royalties
Ongoing payments calculated as a percentage of net sales of the licensed product. Royalties are the most valuable component for the licensor because they provide uncapped participation in the product's commercial success.
- Range: 5-20% of net sales (tiered, often escalating at higher sales thresholds)
- Royalty term: Usually set country by country, running until the later of the last valid patent claim expiring in that country or a fixed period (often 10 years) after first commercial sale
- Key terms: Definition of "net sales" (which GTN deductions are included), geographic scope, anti-stacking provisions (reducing royalties if the licensee must pay other licensors for overlapping IP)
Equity, Cost Sharing, and Profit Splits
Large deals often bolt other instruments onto the three-part core. A strategic equity investment (Pfizer added $100 million of equity to its 2025 3SBio license, discussed below) gives the licensor extra capital. In a co-development and profit-share structure, the licensor funds part of development in exchange for a share of profits, often 50/50 in the US, instead of a royalty. Each term shifts development and commercial risk, so bankers model them explicitly.
Option-to-License: The Growing Trend
Option-to-license (OTL) structures have become a standard tool for pharma buyers that want exposure to an asset before committing full value. A&O Shearman's 2025 review of life sciences deal structures frames the trade: the originator gets non-dilutive capital and validation from a large partner, while the buyer defers major payments until the asset is meaningfully de-risked.
- Option-to-License (OTL)
A licensing structure in which the licensee pays an option fee for the exclusive right, but not the obligation, to take a full license on pre-agreed terms, usually within a set window after a defined data readout. Exercising the option triggers an exercise fee plus the agreed milestones and royalties; letting it lapse returns all rights to the licensor. An option-to-acquire works the same way but covers the purchase of the whole company.
Gilead and Arcus Biosciences show the structure at scale. Their 2020 collaboration gave Gilead options over Arcus's clinical programs, and in November 2021 Gilead exercised options on three of them, including the anti-TIGIT antibody domvanalimab, for option payments totaling $725 million. Exercise converted each option into a co-development deal: the partners share global development costs and split US profits equally, while Gilead pays tiered royalties on sales outside the US. Gilead saw early clinical data before paying most of the price.
Geographic Licensing
Many licensing deals grant rights for specific geographies rather than global rights. The most common structure separates:
- US rights (the largest and highest-priced market, typically half or more of a branded drug's global sales)
- EU rights (the second-largest market, with government-negotiated pricing)
- Japan/Asia rights (the third-largest market, often licensed separately)
- Rest-of-world (smaller markets, often bundled)
Geographic licensing allows the licensor to retain rights where it can commercialize and license rights where it needs a partner, while spreading partner risk across companies. Summit Therapeutics' 2022 deal for Akeso's PD-1/VEGF bispecific ivonescimab is a clean example: Summit paid $500 million upfront, with up to $4.5 billion in regulatory and commercial milestones and low double-digit royalties, for rights in the US, Canada, Europe and Japan, according to Summit's December 2022 announcement. Akeso kept China and the remaining markets.
The China Out-Licensing Wave
The Summit-Akeso structure, a Chinese originator licensing ex-China rights to a Western company, has become one of the defining patterns in pharma BD. In J.P. Morgan's data, China-origin assets made up 39% of big pharma in-licensing deals with upfronts of at least $50 million in 2025, up from 3% in 2022, and collected 32% of those upfront dollars. The headline 2025 example was Pfizer's license of 3SBio's PD-1/VEGF bispecific SSGJ-707: $1.25 billion upfront, up to $4.8 billion in milestones, tiered double-digit royalties and a $100 million equity investment for worldwide rights outside China, plus an option on China itself, per Pfizer's May 2025 announcement.
China-sourced licenses add diligence layers: whether data generated largely in Chinese patients will satisfy the FDA, how manufacturing transfers, and policy exposure such as the BIOSECURE Act.
How Bankers Value Licensing Deals
Healthcare bankers value licensing deals by comparing the expected economics of the deal against alternatives:
For the licensor (biotech): Compare the expected NPV of the licensing deal (probability-weighted upfront + milestones + royalty stream) against the expected NPV of self-development (retaining 100% of economics but bearing 100% of development cost and risk) and against the expected value of a full sale/acquisition.
For the licensee (pharma): Compare the expected NPV of the licensing economics (upfront + milestones + royalties) against the expected NPV of acquiring the entire company (full acquisition premium) or developing a competing product internally.
Probability-Weighting the Biobucks
The core step is weighting each payment by the chance its trigger actually happens, using stage-appropriate probabilities of success. Take a Phase II asset licensed for "up to $1.5 billion," using industry averages of roughly 29% for reaching Phase III and 15% for approval from Phase II, and assuming an 8% chance of hitting the sales milestones:
| Payment | Headline Amount | Probability | Expected Value |
|---|---|---|---|
| Upfront | $100M | 100% | $100M |
| Phase III start | $150M | ~29% | $43.5M |
| FDA approval | $250M | ~15% | $37.5M |
| Sales milestones | $1,000M | ~8% | $80M |
| Total | $1,500M | $261M |
The expected value is about 17% of the headline, before any discounting for time. Discounting each payment back from its expected date, as in a full rNPV model, cuts it further, which is why the upfront deserves far more negotiating weight than its share of the headline suggests.
Royalties get the same treatment, and the total is compared with the cost of an acquisition. A license usually wins when the buyer wants one asset rather than a whole platform, when the target's valuation embeds a large premium, or when early data leave too much uncertainty to justify a full purchase price.
The next article covers the Hatch-Waxman Act, which governs how generics enter the market and creates the legal framework for the branded-to-generic transition.
